Analyst Group: Pharma Equity Group - A Pharma Company with Lower Risk but Equivalent Upside Potential
Pharma Equity Group (“PEG” or “the Company”), through the Company’s subsidiary, Reponex, employs a drug repositioning strategy, which involves finding new uses for active substances used in previous recognized treatments, thus allowing the Company to circumvent phase I trials. PEG has a pipeline of six candidates in Phase II, targeting therapeutic areas such as Peritonitis, Chronic Wounds, IBD, and Colorectal Cancer, where there is currently no adequate treatment. The business strategy involves out-licensing the programs after Phase II to a pharma company capable of bringing the drugs to the market. PEG's strategy enables a capital-light and highly scalable business model, offering a shorter route to market with equivalent upside potential, yet mitigating the typical risks associated with the pharmaceutical industry. Based on an rNPV-model, a potential present value per share of DKK 1.4 is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
This is a press release from Analyst Group regarding the publication of an analysis on Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the analysis. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.